Stockscreener 앱 받기
1.57
3.97%
0.06
시간 외 거래:
1.57
전일 마감가:
$1.51
열려 있는:
$1.51
하루 거래량:
36,388
Relative Volume:
0.35
시가총액:
$21.16M
수익:
-
순이익/손실:
$-9.70M
주가수익비율:
-1.4273
EPS:
-1.1
순현금흐름:
$-8.57M
1주 성능:
+5.37%
1개월 성능:
+11.35%
6개월 성능:
-50.63%
1년 성능:
-70.04%
1일 변동 폭
$1.51
$1.5761
1주일 범위
$1.4207
$1.5761
52주 변동 폭
$0.95
$5.99
마커 테라퓨틱스 Stock (MRKR) Company Profile
명칭
Marker Therapeutics Inc
전화
(713) 400-6400
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
MRKR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.57 | 21.16M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Canaccord Genuity | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Overweight |
| 2021-03-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-03-01 | 개시 | Janney | Buy |
| 2018-12-03 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
마커 테라퓨틱스 주식(MRKR)의 최신 뉴스
Marker Therapeutics Partners with Cellipont for MT-601 Manufacturing - TipRanks
Marker Therapeutics Announces Collaboration with Cellipont Bioservices for cGMP Manufacturing of MT-601 T Cell Therapy - Nasdaq
Marker Therapeutics and Cellipont Bioservices Announce - GlobeNewswire
Marker's Breakthrough Lymphoma Treatment Hits 78% Response Rate, Secures Major Manufacturing Deal - Stock Titan
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Stock Position Decreased by Millennium Management LLC - Defense World
Millennium Management LLC Takes Position in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Millennium Management LLC Invests $31,000 in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World
Millennium Management LLC Purchases Shares of 15,326 Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
Brookline Capital sets $4 target on Marker Therapeutics stock - MSN
Marker Therapeutics Reports Q1 2025 Financial Results - TipRanks
Northern Trust Corp Buys 21,703 Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by Nuveen Asset Management LLC - Defense World
Transcript : Marker Therapeutics, Inc.Special Call - marketscreener.com
Peptide Cancer Vaccine Market Detailed In New Research Report - openPR.com
Marker Therapeutics Reports Positive Impact of Lymphodepletion on MAR-T Cells - MSN
Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma - OncLive
MRKR: Promising Results from Phase 1 APOLLO Study on Lymphoma Treatment | MRKR Stock News - GuruFocus
Marker Therapeutics Reports that Lymphodepletion Improves - GlobeNewswire
Breakthrough: Marker's Cancer Treatment Achieves 78% Response Rate in Lymphoma Patients After CAR-T Failure - Stock Titan
MRKR FY2028 EPS Reduced by Brookline Capital Management - Defense World
Marker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming Webcast - Nasdaq
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies - The Manila Times
Leading Cancer Experts Reveal How MAR-T Technology Could Revolutionize CAR-T Cell Therapy Limitations - Stock Titan
Marker Therapeutics to Spotlight Multi-Antigen Recognizing - GlobeNewswire
Marker Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Hematopoietic stem cell transplantation Market: Investment - openPR.com
Peptide Cancer Vaccine Market Set to Witness Significant Growth - openPR.com
Marker Therapeutics (MRKR) Expected to Announce Earnings on Wednesday - Defense World
Peptide Cancer Vaccine Market Is Booming Worldwide | Marker - openPR.com
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Altesa BioSciences announces Katharine Knobil, M.D. as Chief Medical Officer - PR Newswire
Marker Therapeutics Advances T Cell Therapies in 2024 - TipRanks
LPL Financial LLC Acquires New Holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) - Defense World
Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results - ADVFN
Houston Biotechnology Company Brings Manufacturing Ops Home With New Facility - Bisnow
FibroBiologics opens cell therapy manufacturing space ahead of clinical trials - The Business Journals
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Brookline Capital Management Comments on MRKR Q1 Earnings - Defense World
Marker Therapeutics (NASDAQ:MRKR) Receives Strong-Buy Rating from WBB Securities - The AM Reporter
Brookline Capital Management Estimates MRKR FY2026 Earnings - Defense World
Marker Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Breakthrough: New Alzheimer's Drug Cuts Key Brain Marker by 15%University Study Reveals - Stock Titan
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference - GlobeNewswire
MRKR stock touches 52-week low at $1.12 amid market challenges - Investing.com
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference - The Manila Times
Revolutionary MAR-T Cell Therapy: Marker CEO Reveals Latest Advances in Solid Tumor Treatment - Stock Titan
Marker Therapeutics Advances MT-601 with Promising Results and Strategic Funding - TipRanks
마커 테라퓨틱스 (MRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
마커 테라퓨틱스 주식 (MRKR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
1.45%
0.86%
자본화:
|
볼륨(24시간):